Global Non-insulin Therapies for Diabetes Market, By Product (Oral {Thiazolidinediones (TZDs), Insulin secretagogues, Alpha-glucosidase inhibitors (AGIs), Sulfonylureas, Dipeptidyl peptidase-4 (DPP-4) inhibitors, Sodium-glucose cotransporter-2 (SGLT2) inhibitors, Glinides/Meglitinides, Metformin, Biguanides, & Others} Injectable {Glucagon-like peptide-1 (GLP-1) agonists, Amylin Agonists, & Others}), By Distributor (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, & Others)– Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 – 2027
Industry Trends
Global non-insulin therapies for diabetes market was valued at US$ 61,090.1 million in 2018 and is estimated to reach US$ 105,461.5 million by 2027, growing at a CAGR of 6.3% over the forecast period.
Global Non-Insulin Therapies for Diabetes Market Revenue, 2015 - 2027
Increasing demand for combination therapy and rapid advancements in diabetes treatment are fueling the global non-insulin therapies for diabetes market growth. Combination therapies such as administration of anti-hyperglycemic drugs alone or in combination with insulin used for the treatment of type 2 diabetes. Moreover, from the demand side, surge in people suffering from type 2 diabetes happens to be the primary reason behind growing adoption of various non-insulin therapies across the globe.
As per International Diabetes Foundation (IDF), in 2017, the global prevalence of diabetic patients stood at 425 million, of which 400 million were suffering from type 2 diabetes. Moreover, according to the World Health Organization (WHO), in 2017, diabetes was among top three cause of death with more than 30 million cases in the U.S. alone.
Technological advancements expected to be key growth enabler in the non-insulin therapies for diabetes market. Key vendors operating in the market developed technology platforms such as protein oral delivery (POD) technology (Oramed Pharmaceuticals), Eligen (Emisphere Technologies), Axcess (Diabetology), and PharmFilm Technology (MonoSol Rx) for oral administration of GLP-1 agonists. Moreover, companies such as Panacea and ScinoPharm are in the early stage development of oral capsules for the DPP4 inhibitors.
However, patent expiries of the currently available drugs, and the potential health hazards associated with the use of these inhibitors proves to be major hurdle in market expansion path.
Thiazolidinediones, Insulin secretagogues, alpha-glucosidase inhibitors (AGIs), Sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, Glinides/Meglitinides, Amylin agonists, Metformin, Glucagon like peptide-1 (GLP-1) agonists, and Biguanides are some of the products used in the non-insulin therapies for diabetes market. Oral product segment held the largest market share in 2018 and it is estimated to expand at a rapid rate over the projection period. The growth is attributed to the presence of more oral drugs in the market.
North America non-insulin therapies for diabetes market, held largest market share and is estimated to hold its dominance in years to come. As per the International Diabetes Foundation (IDF), in the U.S. alone approximately, 17,100 new cases of diabetes were reported. This high incidence rate is driving the market growth in the concerned region.
Asia Pacific non-insulin therapies for diabetes market is the most lucrative, owing to surge in diabetes burden in India and China. Both countries collectively has more than 180 million people suffering from diabetes. Moreover, according to the American Diabetes Association (ADA), incidence rate of type 2 diabetes in South East Asia is expected to be more than 150%, by 2035.
The report provides both, qualitative and quantitative research of global non-insulin therapies for diabetes market, it also provides penetrative insights into the rational scenario and favored development methods adopted by key contenders. The report also offers extensive research on the key players in the market and detailed insights into the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by major players are also recognized and analyzed in the report. For each company, the report recognizes its headquarter, competitors, product/service type, application and specification, pricing, and gross margin.
Competitive Landscape
Major industry participants in global non-insulin therapies for diabetes market include Eli Lilly and Company, Eurofarma Laboratorios S.A., GlaxoSmithKline plc, Merck Sharp & Dohme Corp. (subsidiary of Merck & Co., Inc), Novo Nordisk, Luye Pharma Group, and Pfizer Inc. among others. New product launches, merger and acquisition, geographical expansion are some of the major strategies adopted by these players to gain a competitive edge.
- By Product
- Oral
- Thiazolidinediones (TZDs)
- Insulin secretagogues
- Alpha-glucosidase inhibitors (AGIs)
- Sulfonylureas
- Dipeptidyl peptidase-4 (DPP-4) inhibitors
- Sodium-glucose cotransporter-2 (SGLT2) inhibitors
- Glinides/Meglitinides
- Metformin
- Biguanides
- Others
- Injectable
- Glucagon-like peptide-1 (GLP-1) agonists
- Amylin Agonists
- Others
- Oral
- By Distributor
- Hospital Pharmacy
- Retail Pharmacies
- Online Pharmacy
- Others
- By Geography
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Argentina
- Brazil
- Rest of Latin America
- North America
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2013 - 2017
1.2.2. Base
Year: 2018
1.2.3. Forecast
Years: 2019 – 2027
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Non-Insulin Therapies for Diabetes
Market
6. Market Synopsis:
Non-Insulin Therapies for Diabetes Market
7. Non-Insulin Therapies for Diabetes Market Analysis:
Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Non-Insulin Therapies for Diabetes Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Non-Insulin Therapies for Diabetes Market
7.6. Industry
Gross Margin Overview
7.7. Porter’s
Five Force Analysis
8. Global Non-Insulin Therapies for Diabetes Market Analysis and
Forecasts, 2019 – 2027
8.1. Overview
8.1.1. Global
Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn)
8.2. Global
Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By
Product
8.2.1. Oral
(Definition, Market Penetration (2018), Market Estimation (2013 – 2018), Market
Forecast (2019 – 2027), Compound Annual Growth Rate (CAGR), Regional
Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin
America) and Information on Thiazolidinediones (TZDs))
8.2.1.1. Thiazolidinediones (TZDs)
8.2.1.1.1. Insulin secretagogues
8.2.1.1.2. Alpha-glucosidase inhibitors (AGIs)
8.2.1.1.3. Sulfonylureas
8.2.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
8.2.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
8.2.1.1.6. Glinides / Meglitinides
8.2.1.1.7. Metformin
8.2.1.1.8. Biguanides
8.2.1.1.9. Others
8.2.2. Injectable
(Definition, Market Penetration (2018), Market Estimation (2013 – 2018), Market
Forecast (2019 – 2027), Compound Annual Growth Rate (CAGR), Regional
Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin
America) and Information on Glucagon-like peptide-1 (GLP-1) agonists, Amylin
Agonists, Others)
8.2.2.1. Glucagon-like peptide-1 (GLP-1) agonists
8.2.2.2. Amylin Agonists
8.2.2.3. Others
8.3. Key
Segment for Channeling Investments
8.3.1. By
Product
9. Global Non-Insulin Therapies for Diabetes Market Analysis and
Forecasts, 2019 – 2027
9.1. Overview
9.2. Global
Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By
Distributer
9.2.1. Hospital
Pharmacy
9.2.1.1. Definition
9.2.1.2. Market Penetration, 2018
9.2.1.3. Market Estimation, 2013 – 2018
9.2.1.4. Market Forecast, 2019 – 2027
9.2.1.5. Compound Annual Growth Rate (CAGR)
9.2.1.6. Regional Bifurcation
9.2.1.6.1. North America
9.2.1.6.1.1. Market
Estimation, 2013 – 2018
9.2.1.6.1.2. Market
Forecast, 2019 – 2027
9.2.1.6.2. Europe
9.2.1.6.2.1. Market
Estimation, 2013 – 2018
9.2.1.6.2.2. Market
Forecast, 2019 – 2027
9.2.1.6.3. Asia Pacific
9.2.1.6.3.1. Market
Estimation, 2013 – 2018
9.2.1.6.3.2. Market
Forecast, 2019 – 2027
9.2.1.6.4. Middle East and Africa
9.2.1.6.4.1. Market
Estimation, 2013 – 2018
9.2.1.6.4.2. Market
Forecast, 2019 – 2027
9.2.1.6.5. Latin America
9.2.1.6.5.1. Market
Estimation, 2013 – 2018
9.2.1.6.5.2. Market
Forecast, 2019 – 2027
9.2.2. Retail
Pharmacies
9.2.2.1. Definition
9.2.2.2. Market Penetration, 2018
9.2.2.3. Market Estimation, 2013 – 2018
9.2.2.4. Market Forecast, 2019 – 2027
9.2.2.5. Compound Annual Growth Rate (CAGR)
9.2.2.6. Regional Bifurcation
9.2.2.6.1. North America
9.2.2.6.1.1. Market
Estimation, 2013 – 2018
9.2.2.6.1.2. Market
Forecast, 2019 – 2027
9.2.2.6.2. Europe
9.2.2.6.2.1. Market
Estimation, 2013 – 2018
9.2.2.6.2.2. Market
Forecast, 2019 – 2027
9.2.2.6.3. Asia Pacific
9.2.2.6.3.1. Market
Estimation, 2013 – 2018
9.2.2.6.3.2. Market
Forecast, 2019 – 2027
9.2.2.6.4. Middle East and Africa
9.2.2.6.4.1. Market
Estimation, 2013 – 2018
9.2.2.6.4.2. Market
Forecast, 2019 – 2027
9.2.2.6.5. Latin America
9.2.2.6.5.1. Market
Estimation, 2013 – 2018
9.2.2.6.5.2. Market
Forecast, 2019 – 2027
9.2.3. Online
Pharmacy
9.2.3.1. Definition
9.2.3.2. Market Penetration, 2018
9.2.3.3. Market Estimation, 2013 – 2018
9.2.3.4. Market Forecast, 2019 – 2027
9.2.3.5. Compound Annual Growth Rate (CAGR)
9.2.3.6. Regional Bifurcation
9.2.3.6.1. North America
9.2.3.6.1.1. Market
Estimation, 2013 – 2018
9.2.3.6.1.2. Market
Forecast, 2019 – 2027
9.2.3.6.2. Europe
9.2.3.6.2.1. Market
Estimation, 2013 – 2018
9.2.3.6.2.2. Market
Forecast, 2019 – 2027
9.2.3.6.3. Asia Pacific
9.2.3.6.3.1. Market
Estimation, 2013 – 2018
9.2.3.6.3.2. Market
Forecast, 2019 – 2027
9.2.3.6.4. Middle East and Africa
9.2.3.6.4.1. Market
Estimation, 2013 – 2018
9.2.3.6.4.2. Market
Forecast, 2019 – 2027
9.2.3.6.5. Latin America
9.2.3.6.5.1. Market
Estimation, 2013 – 2018
9.2.3.6.5.2. Market
Forecast, 2019 – 2027
9.2.4. Others
9.2.4.1. Definition
9.2.4.2. Market Penetration, 2018
9.2.4.3. Market Estimation, 2013 – 2018
9.2.4.4. Market Forecast, 2019 – 2027
9.2.4.5. Compound Annual Growth Rate (CAGR)
9.2.4.6. Regional Bifurcation
9.2.4.6.1. North America
9.2.4.6.1.1. Market
Estimation, 2013 – 2018
9.2.4.6.1.2. Market
Forecast, 2019 – 2027
9.2.4.6.2. Europe
9.2.4.6.2.1. Market
Estimation, 2013 – 2018
9.2.4.6.2.2. Market
Forecast, 2019 – 2027
9.2.4.6.3. Asia Pacific
9.2.4.6.3.1. Market
Estimation, 2013 – 2018
9.2.4.6.3.2. Market
Forecast, 2019 – 2027
9.2.4.6.4. Middle East and Africa
9.2.4.6.4.1. Market
Estimation, 2013 – 2018
9.2.4.6.4.2. Market
Forecast, 2019 – 2027
9.2.4.6.5. Latin America
9.2.4.6.5.1. Market
Estimation, 2013 – 2018
9.2.4.6.5.2. Market
Forecast, 2019 – 2027
9.3. Key
Segment for Channeling Investments
9.3.1. By
Distributer
10. North America Non-Insulin Therapies for Diabetes Market
Analysis and Forecasts, 2019 - 2027
10.1. Overview
10.1.1. North
America Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn)
10.2. North
America Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and
Forecasts, By Product
10.2.1. Oral
10.2.1.1. Thiazolidinediones (TZDs)
10.2.1.1.1. Insulin secretagogues
10.2.1.1.2. Alpha-glucosidase inhibitors (AGIs)
10.2.1.1.3. Sulfonylureas
10.2.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
10.2.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
10.2.1.1.6. Glinides / Meglitinides
10.2.1.1.7. Metformin
10.2.1.1.8. Biguanides
10.2.1.1.9. Others
10.2.2. Injectable
10.2.2.1. Glucagon-like peptide-1 (GLP-1) agonists
10.2.2.2. Amylin Agonists
10.2.2.3. Others
10.3. North
America Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and
Forecasts, By Distributer
10.3.1. Hospital
Pharmacy
10.3.2. Retail
Pharmacies
10.3.3. Online
Pharmacy
10.3.4. Others
10.4. North
America Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and
Forecasts, By Country
10.4.1. U.S
10.4.1.1. U.S Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn)
and Forecasts, By Product
10.4.1.1.1. Oral
10.4.1.1.1.1. Thiazolidinediones
(TZDs)
10.4.1.1.1.1.1. Insulin secretagogues
10.4.1.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
10.4.1.1.1.1.3. Sulfonylureas
10.4.1.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
10.4.1.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
10.4.1.1.1.1.6. Glinides / Meglitinides
10.4.1.1.1.1.7. Metformin
10.4.1.1.1.1.8. Biguanides
10.4.1.1.1.1.9. Others
10.4.1.1.2. Injectable
10.4.1.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
10.4.1.1.2.2. Amylin
Agonists
10.4.1.1.2.3. Others
10.4.1.2. U.S Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn)
and Forecasts, By Distributer
10.4.1.2.1. Hospital Pharmacy
10.4.1.2.2. Retail Pharmacies
10.4.1.2.3. Online Pharmacy
10.4.1.2.4. Others
10.4.2. Canada
10.4.2.1. Canada Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Product
10.4.2.1.1. Oral
10.4.2.1.1.1. Thiazolidinediones
(TZDs)
10.4.2.1.1.1.1. Insulin secretagogues
10.4.2.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
10.4.2.1.1.1.3. Sulfonylureas
10.4.2.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
10.4.2.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
10.4.2.1.1.1.6. Glinides / Meglitinides
10.4.2.1.1.1.7. Metformin
10.4.2.1.1.1.8. Biguanides
10.4.2.1.1.1.9. Others
10.4.2.1.2. Injectable
10.4.2.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
10.4.2.1.2.2. Amylin
Agonists
10.4.2.1.2.3. Others
10.4.2.2. Canada Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Distributer
10.4.2.2.1. Hospital Pharmacy
10.4.2.2.2. Retail Pharmacies
10.4.2.2.3. Online Pharmacy
10.4.2.2.4. Others
10.4.3. Mexico
10.4.3.1. Mexico Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Product
10.4.3.1.1. Oral
10.4.3.1.1.1. Thiazolidinediones
(TZDs)
10.4.3.1.1.1.1. Insulin secretagogues
10.4.3.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
10.4.3.1.1.1.3. Sulfonylureas
10.4.3.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
10.4.3.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
10.4.3.1.1.1.6. Glinides / Meglitinides
10.4.3.1.1.1.7. Metformin
10.4.3.1.1.1.8. Biguanides
10.4.3.1.1.1.9. Others
10.4.3.1.2. Injectable
10.4.3.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
10.4.3.1.2.2. Amylin
Agonists
10.4.3.1.2.3. Others
10.4.3.2. Mexico Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Distributer
10.4.3.2.1. Hospital Pharmacy
10.4.3.2.2. Retail Pharmacies
10.4.3.2.3. Online Pharmacy
10.4.3.2.4. Others
10.4.4. Rest of
North America
10.4.4.1. Rest of North America Non-Insulin Therapies for Diabetes
Market Revenue (US$ Mn) and Forecasts, By Product
10.4.4.1.1. Oral
10.4.4.1.1.1. Thiazolidinediones
(TZDs)
10.4.4.1.1.1.1. Insulin secretagogues
10.4.4.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
10.4.4.1.1.1.3. Sulfonylureas
10.4.4.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
10.4.4.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
10.4.4.1.1.1.6. Glinides / Meglitinides
10.4.4.1.1.1.7. Metformin
10.4.4.1.1.1.8. Biguanides
10.4.4.1.1.1.9. Others
10.4.4.1.2. Injectable
10.4.4.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
10.4.4.1.2.2. Amylin
Agonists
10.4.4.1.2.3. Others
10.4.4.2. Rest of North America Non-Insulin Therapies for Diabetes
Market Revenue (US$ Mn) and Forecasts, By Distributer
10.4.4.2.1. Hospital Pharmacy
10.4.4.2.2. Retail Pharmacies
10.4.4.2.3. Online Pharmacy
10.4.4.2.4. Others
10.5. Key
Segment for Channeling Investments
10.5.1. By
Country
10.5.2. By
Product
10.5.3. By
Distributer
11. Europe Non-Insulin Therapies for Diabetes Market Analysis and
Forecasts, 2019 - 2027
11.1. Overview
11.1.1. Europe
Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn)
11.2. Europe
Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By
Product
11.2.1. Oral
11.2.1.1. Thiazolidinediones (TZDs)
11.2.1.1.1. Insulin secretagogues
11.2.1.1.2. Alpha-glucosidase inhibitors (AGIs)
11.2.1.1.3. Sulfonylureas
11.2.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
11.2.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
11.2.1.1.6. Glinides / Meglitinides
11.2.1.1.7. Metformin
11.2.1.1.8. Biguanides
11.2.1.1.9. Others
11.2.2. Injectable
11.2.2.1. Glucagon-like peptide-1 (GLP-1) agonists
11.2.2.2. Amylin Agonists
11.2.2.3. Others
11.3. Europe
Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By
Distributer
11.3.1. Hospital
Pharmacy
11.3.2. Retail
Pharmacies
11.3.3. Online
Pharmacy
11.3.4. Others
11.4. Europe
Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By
Country
11.4.1. France
11.4.1.1. France Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Product
11.4.1.1.1. Oral
11.4.1.1.1.1. Thiazolidinediones
(TZDs)
11.4.1.1.1.1.1. Insulin secretagogues
11.4.1.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
11.4.1.1.1.1.3. Sulfonylureas
11.4.1.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
11.4.1.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
11.4.1.1.1.1.6. Glinides / Meglitinides
11.4.1.1.1.1.7. Metformin
11.4.1.1.1.1.8. Biguanides
11.4.1.1.1.1.9. Others
11.4.1.1.2. Injectable
11.4.1.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
11.4.1.1.2.2. Amylin
Agonists
11.4.1.1.2.3. Others
11.4.1.2. France Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Distributer
11.4.1.2.1. Hospital Pharmacy
11.4.1.2.2. Retail Pharmacies
11.4.1.2.3. Online Pharmacy
11.4.1.2.4. Others
11.4.2. The UK
11.4.2.1. The UK Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Product
11.4.2.1.1. Oral
11.4.2.1.1.1. Thiazolidinediones
(TZDs)
11.4.2.1.1.1.1. Insulin secretagogues
11.4.2.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
11.4.2.1.1.1.3. Sulfonylureas
11.4.2.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
11.4.2.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
11.4.2.1.1.1.6. Glinides / Meglitinides
11.4.2.1.1.1.7. Metformin
11.4.2.1.1.1.8. Biguanides
11.4.2.1.1.1.9. Others
11.4.2.1.2. Injectable
11.4.2.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
11.4.2.1.2.2. Amylin
Agonists
11.4.2.1.2.3. Others
11.4.2.2. The UK Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Distributer
11.4.2.2.1. Hospital Pharmacy
11.4.2.2.2. Retail Pharmacies
11.4.2.2.3. Online Pharmacy
11.4.2.2.4. Others
11.4.3. Spain
11.4.3.1. Spain Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Product
11.4.3.1.1. Oral
11.4.3.1.1.1. Thiazolidinediones
(TZDs)
11.4.3.1.1.1.1. Insulin secretagogues
11.4.3.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
11.4.3.1.1.1.3. Sulfonylureas
11.4.3.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
11.4.3.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
11.4.3.1.1.1.6. Glinides / Meglitinides
11.4.3.1.1.1.7. Metformin
11.4.3.1.1.1.8. Biguanides
11.4.3.1.1.1.9. Others
11.4.3.1.2. Injectable
11.4.3.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
11.4.3.1.2.2. Amylin
Agonists
11.4.3.1.2.3. Others
11.4.3.2. Spain Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Distributer
11.4.3.2.1. Hospital Pharmacy
11.4.3.2.2. Retail Pharmacies
11.4.3.2.3. Online Pharmacy
11.4.3.2.4. Others
11.4.4. Germany
11.4.4.1. Germany Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Product
11.4.4.1.1. Oral
11.4.4.1.1.1. Thiazolidinediones
(TZDs)
11.4.4.1.1.1.1. Insulin secretagogues
11.4.4.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
11.4.4.1.1.1.3. Sulfonylureas
11.4.4.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
11.4.4.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
11.4.4.1.1.1.6. Glinides / Meglitinides
11.4.4.1.1.1.7. Metformin
11.4.4.1.1.1.8. Biguanides
11.4.4.1.1.1.9. Others
11.4.4.1.2. Injectable
11.4.4.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
11.4.4.1.2.2. Amylin
Agonists
11.4.4.1.2.3. Others
11.4.4.2. Germany Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Distributer
11.4.4.2.1. Hospital Pharmacy
11.4.4.2.2. Retail Pharmacies
11.4.4.2.3. Online Pharmacy
11.4.4.2.4. Others
11.4.5. Italy
11.4.5.1. Italy Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Product
11.4.5.1.1. Oral
11.4.5.1.1.1. Thiazolidinediones
(TZDs)
11.4.5.1.1.1.1. Insulin secretagogues
11.4.5.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
11.4.5.1.1.1.3. Sulfonylureas
11.4.5.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
11.4.5.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
11.4.5.1.1.1.6. Glinides / Meglitinides
11.4.5.1.1.1.7. Metformin
11.4.5.1.1.1.8. Biguanides
11.4.5.1.1.1.9. Others
11.4.5.1.2. Injectable
11.4.5.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
11.4.5.1.2.2. Amylin
Agonists
11.4.5.1.2.3. Others
11.4.5.2. Italy Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Distributer
11.4.5.2.1. Hospital Pharmacy
11.4.5.2.2. Retail Pharmacies
11.4.5.2.3. Online Pharmacy
11.4.5.2.4. Others
11.4.6. Nordic
Countries
11.4.6.1. Nordic Countries Non-Insulin Therapies for Diabetes Market
Revenue (US$ Mn) and Forecasts, By Product
11.4.6.1.1. Oral
11.4.6.1.1.1. Thiazolidinediones
(TZDs)
11.4.6.1.1.1.1. Insulin secretagogues
11.4.6.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
11.4.6.1.1.1.3. Sulfonylureas
11.4.6.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
11.4.6.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
11.4.6.1.1.1.6. Glinides / Meglitinides
11.4.6.1.1.1.7. Metformin
11.4.6.1.1.1.8. Biguanides
11.4.6.1.1.1.9. Others
11.4.6.1.2. Injectable
11.4.6.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
11.4.6.1.2.2. Amylin
Agonists
11.4.6.1.2.3. Others
11.4.6.2. Nordic Countries Non-Insulin Therapies for Diabetes Market
Revenue (US$ Mn) and Forecasts, By Distributer
11.4.6.2.1. Hospital Pharmacy
11.4.6.2.2. Retail Pharmacies
11.4.6.2.3. Online Pharmacy
11.4.6.2.4. Others
11.4.6.3. Nordic Countries Non-Insulin Therapies for Diabetes Market
Revenue (US$ Mn) and Forecasts, By Country
11.4.6.3.1. Denmark
11.4.6.3.2. Finland
11.4.6.3.3. Iceland
11.4.6.3.4. Sweden
11.4.6.3.5. Norway
11.4.7. Benelux
Union
11.4.7.1. Benelux Union Non-Insulin Therapies for Diabetes Market
Revenue (US$ Mn) and Forecasts, By Product
11.4.7.1.1. Oral
11.4.7.1.1.1. Thiazolidinediones
(TZDs)
11.4.7.1.1.1.1. Insulin secretagogues
11.4.7.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
11.4.7.1.1.1.3. Sulfonylureas
11.4.7.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
11.4.7.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
11.4.7.1.1.1.6. Glinides / Meglitinides
11.4.7.1.1.1.7. Metformin
11.4.7.1.1.1.8. Biguanides
11.4.7.1.1.1.9. Others
11.4.7.1.2. Injectable
11.4.7.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
11.4.7.1.2.2. Amylin
Agonists
11.4.7.1.2.3. Others
11.4.7.2. Benelux Union Non-Insulin Therapies for Diabetes Market
Revenue (US$ Mn) and Forecasts, By Distributer
11.4.7.2.1. Hospital Pharmacy
11.4.7.2.2. Retail Pharmacies
11.4.7.2.3. Online Pharmacy
11.4.7.2.4. Others
11.4.7.3. Benelux Union Non-Insulin Therapies for Diabetes Market
Revenue (US$ Mn) and Forecasts, By Country
11.4.7.3.1. Belgium
11.4.7.3.2. The Netherlands
11.4.7.3.3. Luxembourg
11.4.8. Rest of
Europe
11.4.8.1. Rest of Europe Non-Insulin Therapies for Diabetes Market
Revenue (US$ Mn) and Forecasts, By Product
11.4.8.1.1. Oral
11.4.8.1.1.1. Thiazolidinediones
(TZDs)
11.4.8.1.1.1.1. Insulin secretagogues
11.4.8.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
11.4.8.1.1.1.3. Sulfonylureas
11.4.8.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
11.4.8.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
11.4.8.1.1.1.6. Glinides / Meglitinides
11.4.8.1.1.1.7. Metformin
11.4.8.1.1.1.8. Biguanides
11.4.8.1.1.1.9. Others
11.4.8.1.2. Injectable
11.4.8.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
11.4.8.1.2.2. Amylin
Agonists
11.4.8.1.2.3. Others
11.4.8.2. Rest of Europe Non-Insulin Therapies for Diabetes Market
Revenue (US$ Mn) and Forecasts, By Distributer
11.4.8.2.1. Hospital Pharmacy
11.4.8.2.2. Retail Pharmacies
11.4.8.2.3. Online Pharmacy
11.4.8.2.4. Others
11.5. Key
Segment for Channeling Investments
11.5.1. By
Country
11.5.2. By
Product
11.5.3. By
Distributer
12. Asia Pacific Non-Insulin Therapies for Diabetes Market
Analysis and Forecasts, 2019 - 2027
12.1. Overview
12.1.1. Asia
Pacific Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn)
12.2. Asia
Pacific Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and
Forecasts, By Product
12.2.1. Oral
12.2.1.1. Thiazolidinediones (TZDs)
12.2.1.1.1. Insulin secretagogues
12.2.1.1.2. Alpha-glucosidase inhibitors (AGIs)
12.2.1.1.3. Sulfonylureas
12.2.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
12.2.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
12.2.1.1.6. Glinides / Meglitinides
12.2.1.1.7. Metformin
12.2.1.1.8. Biguanides
12.2.1.1.9. Others
12.2.2. Injectable
12.2.2.1. Glucagon-like peptide-1 (GLP-1) agonists
12.2.2.2. Amylin Agonists
12.2.2.3. Others
12.3. Asia
Pacific Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and
Forecasts, By Distributer
12.3.1. Hospital
Pharmacy
12.3.2. Retail Pharmacies
12.3.3. Online
Pharmacy
12.3.4. Others
12.4. Asia
Pacific Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and
Forecasts, By Country
12.4.1. China
12.4.1.1. China Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Product
12.4.1.1.1. Oral
12.4.1.1.1.1. Thiazolidinediones
(TZDs)
12.4.1.1.1.1.1. Insulin secretagogues
12.4.1.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
12.4.1.1.1.1.3. Sulfonylureas
12.4.1.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
12.4.1.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
12.4.1.1.1.1.6. Glinides / Meglitinides
12.4.1.1.1.1.7. Metformin
12.4.1.1.1.1.8. Biguanides
12.4.1.1.1.1.9. Others
12.4.1.1.2. Injectable
12.4.1.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
12.4.1.1.2.2. Amylin
Agonists
12.4.1.1.2.3. Others
12.4.1.2. China Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Distributer
12.4.1.2.1. Hospital Pharmacy
12.4.1.2.2. Retail Pharmacies
12.4.1.2.3. Online Pharmacy
12.4.1.2.4. Others
12.4.2. Japan
12.4.2.1. Japan Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Product
12.4.2.1.1. Oral
12.4.2.1.1.1. Thiazolidinediones
(TZDs)
12.4.2.1.1.1.1. Insulin secretagogues
12.4.2.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
12.4.2.1.1.1.3. Sulfonylureas
12.4.2.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
12.4.2.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
12.4.2.1.1.1.6. Glinides / Meglitinides
12.4.2.1.1.1.7. Metformin
12.4.2.1.1.1.8. Biguanides
12.4.2.1.1.1.9. Others
12.4.2.1.2. Injectable
12.4.2.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
12.4.2.1.2.2. Amylin
Agonists
12.4.2.1.2.3. Others
12.4.2.2. Japan Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Distributer
12.4.2.2.1. Hospital Pharmacy
12.4.2.2.2. Retail Pharmacies
12.4.2.2.3. Online Pharmacy
12.4.2.2.4. Others
12.4.3. India
12.4.3.1. India Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Product
12.4.3.1.1. Oral
12.4.3.1.1.1. Thiazolidinediones
(TZDs)
12.4.3.1.1.1.1. Insulin secretagogues
12.4.3.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
12.4.3.1.1.1.3. Sulfonylureas
12.4.3.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
12.4.3.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
12.4.3.1.1.1.6. Glinides / Meglitinides
12.4.3.1.1.1.7. Metformin
12.4.3.1.1.1.8. Biguanides
12.4.3.1.1.1.9. Others
12.4.3.1.2. Injectable
12.4.3.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
12.4.3.1.2.2. Amylin
Agonists
12.4.3.1.2.3. Others
12.4.3.2. India Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Distributer
12.4.3.2.1. Hospital Pharmacy
12.4.3.2.2. Retail Pharmacies
12.4.3.2.3. Online Pharmacy
12.4.3.2.4. Others
12.4.4. New
Zealand
12.4.4.1. New Zealand Non-Insulin Therapies for Diabetes Market Revenue
(US$ Mn) and Forecasts, By Product
12.4.4.1.1. Oral
12.4.4.1.1.1. Thiazolidinediones
(TZDs)
12.4.4.1.1.1.1. Insulin secretagogues
12.4.4.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
12.4.4.1.1.1.3. Sulfonylureas
12.4.4.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
12.4.4.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
12.4.4.1.1.1.6. Glinides / Meglitinides
12.4.4.1.1.1.7. Metformin
12.4.4.1.1.1.8. Biguanides
12.4.4.1.1.1.9. Others
12.4.4.1.2. Injectable
12.4.4.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
12.4.4.1.2.2. Amylin
Agonists
12.4.4.1.2.3. Others
12.4.4.2. New Zealand Non-Insulin Therapies for Diabetes Market Revenue
(US$ Mn) and Forecasts, By Distributer
12.4.4.2.1. Hospital Pharmacy
12.4.4.2.2. Retail Pharmacies
12.4.4.2.3. Online Pharmacy
12.4.4.2.4. Others
12.4.5. Australia
12.4.5.1. Australia Non-Insulin Therapies for Diabetes Market Revenue
(US$ Mn) and Forecasts, By Product
12.4.5.1.1. Oral
12.4.5.1.1.1. Thiazolidinediones
(TZDs)
12.4.5.1.1.1.1. Insulin secretagogues
12.4.5.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
12.4.5.1.1.1.3. Sulfonylureas
12.4.5.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
12.4.5.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
12.4.5.1.1.1.6. Glinides / Meglitinides
12.4.5.1.1.1.7. Metformin
12.4.5.1.1.1.8. Biguanides
12.4.5.1.1.1.9. Others
12.4.5.1.2. Injectable
12.4.5.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
12.4.5.1.2.2. Amylin
Agonists
12.4.5.1.2.3. Others
12.4.5.2. Australia Non-Insulin Therapies for Diabetes Market Revenue
(US$ Mn) and Forecasts, By Distributer
12.4.5.2.1. Hospital Pharmacy
12.4.5.2.2. Retail Pharmacies
12.4.5.2.3. Online Pharmacy
12.4.5.2.4. Others
12.4.6. South
Korea
12.4.6.1. South Korea Non-Insulin Therapies for Diabetes Market Revenue
(US$ Mn) and Forecasts, By Product
12.4.6.1.1. Oral
12.4.6.1.1.1. Thiazolidinediones
(TZDs)
12.4.6.1.1.1.1. Insulin secretagogues
12.4.6.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
12.4.6.1.1.1.3. Sulfonylureas
12.4.6.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
12.4.6.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
12.4.6.1.1.1.6. Glinides / Meglitinides
12.4.6.1.1.1.7. Metformin
12.4.6.1.1.1.8. Biguanides
12.4.6.1.1.1.9. Others
12.4.6.1.2. Injectable
12.4.6.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
12.4.6.1.2.2. Amylin
Agonists
12.4.6.1.2.3. Others
12.4.6.2. South Korea Non-Insulin Therapies for Diabetes Market Revenue
(US$ Mn) and Forecasts, By Distributer
12.4.6.2.1. Hospital Pharmacy
12.4.6.2.2. Retail Pharmacies
12.4.6.2.3. Online Pharmacy
12.4.6.2.4. Others
12.4.7. Southeast
Asia
12.4.7.1. Southeast Asia Non-Insulin Therapies for Diabetes Market
Revenue (US$ Mn) and Forecasts, By Product
12.4.7.1.1. Oral
12.4.7.1.1.1. Thiazolidinediones
(TZDs)
12.4.7.1.1.1.1. Insulin secretagogues
12.4.7.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
12.4.7.1.1.1.3. Sulfonylureas
12.4.7.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
12.4.7.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
12.4.7.1.1.1.6. Glinides / Meglitinides
12.4.7.1.1.1.7. Metformin
12.4.7.1.1.1.8. Biguanides
12.4.7.1.1.1.9. Others
12.4.7.1.2. Injectable
12.4.7.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
12.4.7.1.2.2. Amylin
Agonists
12.4.7.1.2.3. Others
12.4.7.2. Southeast Asia Non-Insulin Therapies for Diabetes Market
Revenue (US$ Mn) and Forecasts, By Distributer
12.4.7.2.1. Hospital Pharmacy
12.4.7.2.2. Retail Pharmacies
12.4.7.2.3. Online Pharmacy
12.4.7.2.4. Others
12.4.7.3. Southeast Asia Non-Insulin Therapies for Diabetes Market
Revenue (US$ Mn) and Forecasts, By Country
12.4.7.3.1. Indonesia
12.4.7.3.2. Thailand
12.4.7.3.3. Malaysia
12.4.7.3.4. Singapore
12.4.7.3.5. Rest of Southeast Asia
12.4.8. Rest of
Asia Pacific
12.4.8.1. Rest of Asia Pacific Non-Insulin Therapies for Diabetes Market
Revenue (US$ Mn) and Forecasts, By Product
12.4.8.1.1. Oral
12.4.8.1.1.1. Thiazolidinediones
(TZDs)
12.4.8.1.1.1.1. Insulin secretagogues
12.4.8.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
12.4.8.1.1.1.3. Sulfonylureas
12.4.8.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
12.4.8.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
12.4.8.1.1.1.6. Glinides / Meglitinides
12.4.8.1.1.1.7. Metformin
12.4.8.1.1.1.8. Biguanides
12.4.8.1.1.1.9. Others
12.4.8.1.2. Injectable
12.4.8.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
12.4.8.1.2.2. Amylin
Agonists
12.4.8.1.2.3. Others
12.4.8.2. Rest of Asia Pacific Non-Insulin Therapies for Diabetes Market
Revenue (US$ Mn) and Forecasts, By Distributer
12.4.8.2.1. Hospital Pharmacy
12.4.8.2.2. Retail Pharmacies
12.4.8.2.3. Online Pharmacy
12.4.8.2.4. Others
12.5. Key
Segment for Channeling Investments
12.5.1. By
Country
12.5.2. By
Product
12.5.3. By
Distributer
13. Middle East and Africa Non-Insulin Therapies for Diabetes
Market Analysis and Forecasts, 2019 - 2027
13.1. Overview
13.1.1. Middle
East and Africa Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn)
13.2. Middle
East and Africa Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and
Forecasts, By Product
13.2.1. Oral
13.2.1.1. Thiazolidinediones (TZDs)
13.2.1.1.1. Insulin secretagogues
13.2.1.1.2. Alpha-glucosidase inhibitors (AGIs)
13.2.1.1.3. Sulfonylureas
13.2.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
13.2.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
13.2.1.1.6. Glinides / Meglitinides
13.2.1.1.7. Metformin
13.2.1.1.8. Biguanides
13.2.1.1.9. Others
13.2.2. Injectable
13.2.2.1. Glucagon-like peptide-1 (GLP-1) agonists
13.2.2.2. Amylin Agonists
13.2.2.3. Others
13.3. Middle
East and Africa Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and
Forecasts, By Distributer
13.3.1. Hospital
Pharmacy
13.3.2. Retail
Pharmacies
13.3.3. Online
Pharmacy
13.3.4. Others
13.4. Middle
East and Africa Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and
Forecasts, By Country
13.4.1. Saudi
Arabia
13.4.1.1. Saudi Arabia Non-Insulin Therapies for Diabetes Market Revenue
(US$ Mn) and Forecasts, By Product
13.4.1.1.1. Oral
13.4.1.1.1.1. Thiazolidinediones
(TZDs)
13.4.1.1.1.1.1. Insulin secretagogues
13.4.1.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
13.4.1.1.1.1.3. Sulfonylureas
13.4.1.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
13.4.1.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
13.4.1.1.1.1.6. Glinides / Meglitinides
13.4.1.1.1.1.7. Metformin
13.4.1.1.1.1.8. Biguanides
13.4.1.1.1.1.9. Others
13.4.1.1.2. Injectable
13.4.1.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
13.4.1.1.2.2. Amylin
Agonists
13.4.1.1.2.3. Others
13.4.1.2. Saudi Arabia Non-Insulin Therapies for Diabetes Market Revenue
(US$ Mn) and Forecasts, By Distributer
13.4.1.2.1. Hospital Pharmacy
13.4.1.2.2. Retail Pharmacies
13.4.1.2.3. Online Pharmacy
13.4.1.2.4. Others
13.4.2. UAE
13.4.2.1. UAE Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn)
and Forecasts, By Product
13.4.2.1.1. Oral
13.4.2.1.1.1. Thiazolidinediones
(TZDs)
13.4.2.1.1.1.1. Insulin secretagogues
13.4.2.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
13.4.2.1.1.1.3. Sulfonylureas
13.4.2.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
13.4.2.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
13.4.2.1.1.1.6. Glinides / Meglitinides
13.4.2.1.1.1.7. Metformin
13.4.2.1.1.1.8. Biguanides
13.4.2.1.1.1.9. Others
13.4.2.1.2. Injectable
13.4.2.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
13.4.2.1.2.2. Amylin
Agonists
13.4.2.1.2.3. Others
13.4.2.2. UAE Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn)
and Forecasts, By Distributer
13.4.2.2.1. Hospital Pharmacy
13.4.2.2.2. Retail Pharmacies
13.4.2.2.3. Online Pharmacy
13.4.2.2.4. Others
13.4.3. Egypt
13.4.3.1. Egypt Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Product
13.4.3.1.1. Oral
13.4.3.1.1.1. Thiazolidinediones
(TZDs)
13.4.3.1.1.1.1. Insulin secretagogues
13.4.3.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
13.4.3.1.1.1.3. Sulfonylureas
13.4.3.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
13.4.3.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
13.4.3.1.1.1.6. Glinides / Meglitinides
13.4.3.1.1.1.7. Metformin
13.4.3.1.1.1.8. Biguanides
13.4.3.1.1.1.9. Others
13.4.3.1.2. Injectable
13.4.3.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
13.4.3.1.2.2. Amylin
Agonists
13.4.3.1.2.3. Others
13.4.3.2. Egypt Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Distributer
13.4.3.2.1. Hospital Pharmacy
13.4.3.2.2. Retail Pharmacies
13.4.3.2.3. Online Pharmacy
13.4.3.2.4. Others
13.4.4. Kuwait
13.4.4.1. Kuwait Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Product
13.4.4.1.1. Oral
13.4.4.1.1.1. Thiazolidinediones
(TZDs)
13.4.4.1.1.1.1. Insulin secretagogues
13.4.4.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
13.4.4.1.1.1.3. Sulfonylureas
13.4.4.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
13.4.4.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
13.4.4.1.1.1.6. Glinides / Meglitinides
13.4.4.1.1.1.7. Metformin
13.4.4.1.1.1.8. Biguanides
13.4.4.1.1.1.9. Others
13.4.4.1.2. Injectable
13.4.4.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
13.4.4.1.2.2. Amylin
Agonists
13.4.4.1.2.3. Others
13.4.4.2. Kuwait Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Distributer
13.4.4.2.1. Hospital Pharmacy
13.4.4.2.2. Retail Pharmacies
13.4.4.2.3. Online Pharmacy
13.4.4.2.4. Others
13.4.5. South
Africa
13.4.5.1. South Africa Non-Insulin Therapies for Diabetes Market Revenue
(US$ Mn) and Forecasts, By Product
13.4.5.1.1. Oral
13.4.5.1.1.1. Thiazolidinediones
(TZDs)
13.4.5.1.1.1.1. Insulin secretagogues
13.4.5.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
13.4.5.1.1.1.3. Sulfonylureas
13.4.5.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
13.4.5.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
13.4.5.1.1.1.6. Glinides / Meglitinides
13.4.5.1.1.1.7. Metformin
13.4.5.1.1.1.8. Biguanides
13.4.5.1.1.1.9. Others
13.4.5.1.2. Injectable
13.4.5.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
13.4.5.1.2.2. Amylin
Agonists
13.4.5.1.2.3. Others
13.4.5.2. South Africa Non-Insulin Therapies for Diabetes Market Revenue
(US$ Mn) and Forecasts, By Distributer
13.4.5.2.1. Hospital Pharmacy
13.4.5.2.2. Retail Pharmacies
13.4.5.2.3. Online Pharmacy
13.4.5.2.4. Others
13.4.6. Rest of
Middle East & Africa
13.4.6.1. Rest of Middle East & Africa Non-Insulin Therapies for
Diabetes Market Revenue (US$ Mn) and Forecasts, By Product
13.4.6.1.1. Oral
13.4.6.1.1.1. Thiazolidinediones
(TZDs)
13.4.6.1.1.1.1. Insulin secretagogues
13.4.6.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
13.4.6.1.1.1.3. Sulfonylureas
13.4.6.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
13.4.6.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
13.4.6.1.1.1.6. Glinides / Meglitinides
13.4.6.1.1.1.7. Metformin
13.4.6.1.1.1.8. Biguanides
13.4.6.1.1.1.9. Others
13.4.6.1.2. Injectable
13.4.6.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
13.4.6.1.2.2. Amylin
Agonists
13.4.6.1.2.3. Others
13.4.6.2. Rest of Middle East & Africa Non-Insulin Therapies for
Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer
13.4.6.2.1. Hospital Pharmacy
13.4.6.2.2. Retail Pharmacies
13.4.6.2.3. Online Pharmacy
13.4.6.2.4. Others
13.5. Key
Segment for Channeling Investments
13.5.1. By
Country
13.5.2. By
Product
13.5.3. By
Distributer
14. Latin America Non-Insulin Therapies for Diabetes Market
Analysis and Forecasts, 2019 - 2027
14.1. Overview
14.1.1. Latin
America Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn)
14.2. Latin
America Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and
Forecasts, By Product
14.2.1. Oral
14.2.1.1. Thiazolidinediones (TZDs)
14.2.1.1.1. Insulin secretagogues
14.2.1.1.2. Alpha-glucosidase inhibitors (AGIs)
14.2.1.1.3. Sulfonylureas
14.2.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
14.2.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
14.2.1.1.6. Glinides / Meglitinides
14.2.1.1.7. Metformin
14.2.1.1.8. Biguanides
14.2.1.1.9. Others
14.2.2. Injectable
14.2.2.1. Glucagon-like peptide-1 (GLP-1) agonists
14.2.2.2. Amylin Agonists
14.2.2.3. Others
14.3. Latin
America Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and
Forecasts, By Distributer
14.3.1. Hospital
Pharmacy
14.3.2. Retail
Pharmacies
14.3.3. Online
Pharmacy
14.3.4. Others
14.4. Latin
America Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and
Forecasts, By Country
14.4.1. Brazil
14.4.1.1. Brazil Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Product
14.4.1.1.1. Oral
14.4.1.1.1.1. Thiazolidinediones
(TZDs)
14.4.1.1.1.1.1. Insulin secretagogues
14.4.1.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
14.4.1.1.1.1.3. Sulfonylureas
14.4.1.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
14.4.1.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
14.4.1.1.1.1.6. Glinides / Meglitinides
14.4.1.1.1.1.7. Metformin
14.4.1.1.1.1.8. Biguanides
14.4.1.1.1.1.9. Others
14.4.1.1.2. Injectable
14.4.1.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
14.4.1.1.2.2. Amylin
Agonists
14.4.1.1.2.3. Others
14.4.1.2. Brazil Non-Insulin Therapies for Diabetes Market Revenue (US$
Mn) and Forecasts, By Distributer
14.4.1.2.1. Hospital Pharmacy
14.4.1.2.2. Retail Pharmacies
14.4.1.2.3. Online Pharmacy
14.4.1.2.4. Others
14.4.2. Argentina
14.4.2.1. Argentina Non-Insulin Therapies for Diabetes Market Revenue
(US$ Mn) and Forecasts, By Product
14.4.2.1.1. Oral
14.4.2.1.1.1. Thiazolidinediones
(TZDs)
14.4.2.1.1.1.1. Insulin secretagogues
14.4.2.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
14.4.2.1.1.1.3. Sulfonylureas
14.4.2.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
14.4.2.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
14.4.2.1.1.1.6. Glinides / Meglitinides
14.4.2.1.1.1.7. Metformin
14.4.2.1.1.1.8. Biguanides
14.4.2.1.1.1.9. Others
14.4.2.1.2. Injectable
14.4.2.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
14.4.2.1.2.2. Amylin
Agonists
14.4.2.1.2.3. Others
14.4.2.2. Argentina Non-Insulin Therapies for Diabetes Market Revenue
(US$ Mn) and Forecasts, By Distributer
14.4.2.2.1. Hospital Pharmacy
14.4.2.2.2. Retail Pharmacies
14.4.2.2.3. Online Pharmacy
14.4.2.2.4. Others
14.4.3. Rest of
Latin America
14.4.3.1. Rest of Latin America Non-Insulin Therapies for Diabetes
Market Revenue (US$ Mn) and Forecasts, By Product
14.4.3.1.1. Oral
14.4.3.1.1.1. Thiazolidinediones
(TZDs)
14.4.3.1.1.1.1. Insulin secretagogues
14.4.3.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)
14.4.3.1.1.1.3. Sulfonylureas
14.4.3.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors
14.4.3.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
14.4.3.1.1.1.6. Glinides / Meglitinides
14.4.3.1.1.1.7. Metformin
14.4.3.1.1.1.8. Biguanides
14.4.3.1.1.1.9. Others
14.4.3.1.2. Injectable
14.4.3.1.2.1. Glucagon-like
peptide-1 (GLP-1) agonists
14.4.3.1.2.2. Amylin
Agonists
14.4.3.1.2.3. Others
14.4.3.2. Rest of Latin America Non-Insulin Therapies for Diabetes
Market Revenue (US$ Mn) and Forecasts, By Distributer
14.4.3.2.1. Hospital Pharmacy
14.4.3.2.2. Retail Pharmacies
14.4.3.2.3. Online Pharmacy
14.4.3.2.4. Others
14.5. Key
Segment for Channeling Investments
14.5.1. By
Country
14.5.2. By
Product
14.5.3. By
Distributer
15. Competitive Benchmarking
15.1. Brand
Benchmarking
15.2. Market
Share Analysis, 2018
15.3. Global
Presence and Growth Strategies
15.3.1. Mergers
and Acquisitions
15.3.2. Product
Launches
15.3.3. Investments
Trends
15.3.4. R&D
Initiatives
16. Player Profiles
16.1. Alkem
Labs.
16.1.1. Company
Details
16.1.2. Company
Overview
16.1.3. Product
Offerings
16.1.4. Key
Developments
16.1.5. Financial
Analysis
16.1.6. SWOT
Analysis
16.1.7. Business
Strategies
16.2. Eli Lilly
and Company
16.2.1. Company
Details
16.2.2. Company
Overview
16.2.3. Product
Offerings
16.2.4. Key Developments
16.2.5. Financial
Analysis
16.2.6. SWOT
Analysis
16.2.7. Business
Strategies
16.3. Emisphere
Technologies
16.3.1. Company
Details
16.3.2. Company
Overview
16.3.3. Product
Offerings
16.3.4. Key
Developments
16.3.5. Financial
Analysis
16.3.6. SWOT
Analysis
16.3.7. Business
Strategies
16.4. Eurofarma
Laboratórios S.A.
16.4.1. Company
Details
16.4.2. Company
Overview
16.4.3. Product
Offerings
16.4.4. Key
Developments
16.4.5. Financial
Analysis
16.4.6. SWOT
Analysis
16.4.7. Business
Strategies
16.5. GEROPHARM
16.5.1. Company
Details
16.5.2. Company
Overview
16.5.3. Product
Offerings
16.5.4. Key
Developments
16.5.5. Financial
Analysis
16.5.6. SWOT
Analysis
16.5.7. Business
Strategies
16.6. GlaxoSmithKline
plc.
16.6.1. Company
Details
16.6.2. Company
Overview
16.6.3. Product
Offerings
16.6.4. Key
Developments
16.6.5. Financial
Analysis
16.6.6. SWOT
Analysis
16.6.7. Business
Strategies
16.7. Intarcia
Therapeutics, Inc.
16.7.1. Company
Details
16.7.2. Company
Overview
16.7.3. Product
Offerings
16.7.4. Key
Developments
16.7.5. Financial
Analysis
16.7.6. SWOT
Analysis
16.7.7. Business
Strategies
16.8. Jiangsu
Hengrui Medicine
16.8.1. Company
Details
16.8.2. Company
Overview
16.8.3. Product
Offerings
16.8.4. Key
Developments
16.8.5. Financial
Analysis
16.8.6. SWOT
Analysis
16.8.7. Business
Strategies
16.9. Luye
Pharma Group
16.9.1. Company
Details
16.9.2. Company
Overview
16.9.3. Product
Offerings
16.9.4. Key
Developments
16.9.5. Financial
Analysis
16.9.6. SWOT
Analysis
16.9.7. Business
Strategies
16.10. Merck
Sharp & Dohme Corp.
16.10.1. Company
Details
16.10.2. Company
Overview
16.10.3. Product
Offerings
16.10.4. Key
Developments
16.10.5. Financial
Analysis
16.10.6. SWOT
Analysis
16.10.7. Business
Strategies
16.11. Novo
Nordisk
16.11.1. Company
Details
16.11.2. Company
Overview
16.11.3. Product
Offerings
16.11.4. Key
Developments
16.11.5. Financial
Analysis
16.11.6. SWOT
Analysis
16.11.7. Business
Strategies
16.12. Pfizer
Inc.
16.12.1. Company
Details
16.12.2. Company
Overview
16.12.3. Product
Offerings
16.12.4. Key
Developments
16.12.5. Financial
Analysis
16.12.6. SWOT
Analysis
16.12.7. Business
Strategies
16.13. Satrix
16.13.1. Company
Details
16.13.2. Company
Overview
16.13.3. Product
Offerings
16.13.4. Key
Developments
16.13.5. Financial
Analysis
16.13.6. SWOT
Analysis
16.13.7. Business
Strategies
16.14. Servier
16.14.1. Company
Details
16.14.2. Company
Overview
16.14.3. Product
Offerings
16.14.4. Key
Developments
16.14.5. Financial
Analysis
16.14.6. SWOT
Analysis
16.14.7. Business
Strategies
16.15. Sumitomo
Dainippon Pharma Co., Ltd.
16.15.1. Company
Details
16.15.2. Company
Overview
16.15.3. Product
Offerings
16.15.4. Key
Developments
16.15.5. Financial
Analysis
16.15.6. SWOT
Analysis
16.15.7. Business
Strategies
16.16. Syneos
Health
16.16.1. Company
Details
16.16.2. Company
Overview
16.16.3. Product
Offerings
16.16.4. Key
Developments
16.16.5. Financial
Analysis
16.16.6. SWOT
Analysis
16.16.7. Business
Strategies
16.17. Takeda
Pharmaceutical Company Limited
16.17.1. Company
Details
16.17.2. Company
Overview
16.17.3. Product
Offerings
16.17.4. Key
Developments
16.17.5. Financial
Analysis
16.17.6. SWOT
Analysis
16.17.7. Business
Strategies
16.18. Other
industry participants
17. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.